Bioequivalence of indinavir capsules in healthy volunteers

1. Wainberg MA. Generic HIV drugs-enlightened policy for global health. N Engl J Med. 2005; 352:747-50.10.1056/NEJMp048356Search in Google Scholar

2. Bartlett JA, Muro EP. Generic and branded drugs for the treatment of people living with HIV/AIDS. J Int Assoc Physicians AIDS Care. 2007; 6:15-23.10.1177/1545109707299856Search in Google Scholar

3. Hugen PWH, Burger DM, ter Hofstede HJM, Koopmans PP, Hekster YA. Development of an indinavir oral liquid for children. Am J Health Syst Pharm. 2000; 57:1332-9.10.1093/ajhp/57.14.1332Search in Google Scholar

4. Yeh KC, Deutsch PJ, Haddix H, Hesney M, Hoagland V, Ju WD, et al. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother. 1998; 42:332-8.10.1128/AAC.42.2.332Search in Google Scholar

5. Hsu A, Granneman GR, Cao G, Carothers L, Japour A, El-Shourbagy T, et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother. 1998; 42:2784-91.10.1128/AAC.42.11.2784Search in Google Scholar

6. The United States Pharmacopoeial Convention, Inc. The United States Pharmacopeia 26 / National Formulary 21. Rockville, USA; 2003.Search in Google Scholar

7. Drug Control Division. Thailand Guidelines for the Conduct of Bioavailability and Bioequivalence Studies. Bangkok, Thailand: Food and Drug Administration, Ministry of Public Health; 2000.Search in Google Scholar

8. Poirier JM, Robidou P, Jaillon P. Determination of indinavir in plasma by solid-phase extraction and column liquid chromatography. Ther Drug Monit. 1999; 21:404-10.10.1097/00007691-199908000-00004Search in Google Scholar

9. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for Industry, Bioanalytical Method Validation. Available from: http://www.fda.gov/cder/guidance/index.htm, 2001/[2 June 2005].Search in Google Scholar

10. Wonnacott RJ, Wonnacott TH, editors. Econometrics. New York:John Wiley & Sons, 1970; p. 132. Search in Google Scholar

11. Association of Southeast Asian Nations (ASEAN), Consultative Committee for Standards and Quality- Pharmaceutical Product Working Group. Guidelines for the Conduct of Bioavailability and Bioequivalence Studies. 2004.Search in Google Scholar

12. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry. Statistical Approaches to Establishing Bioequivalence. January 2001.Search in Google Scholar

13. Kraft WK, McCrea JB, Winchell GA, Carides A, Lowry R, Woolf EJ, et al. Indinavir and rifabutin drug interactions in healthy volunteers. J Clin Pharmacol. 2004; 44:305-13.10.1177/0091270003262807Open DOISearch in Google Scholar

14. Burger D, Boyd M, Duncombe C, Felderhof M, Mahanontharit A, Ruxrungtham K, et al. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother. 2003; 51:1231-8.10.1093/jac/dkg198Search in Google Scholar

15. Schiffman SS, Zervakis J, Heffron S, Heald AE. Effect of protease inhibitors on the sense of taste. Nutrition. 1999; 15:767-72.10.1016/S0899-9007(99)00152-5Open DOISearch in Google Scholar